Scholar Rock Holding (SRRK) Capital Expenditures (2017 - 2026)
Scholar Rock Holding's quarterly Capital Expenditures came in at $68000.0 in Q1 2026, down 74.91% year-on-year from $271000.0 in Q1 2025, and up 112.5% quarter-over-quarter from $32000.0 in Q4 2025.
Scholar Rock Holding has reported Capital Expenditures for 10 years, with the latest figure at $68000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 74.91% year-over-year to $68000.0; the trailing twelve-month figure through Mar 2026 stood at $399000.0 (up 12.08% YoY), and the FY2025 full-year result was $602000.0, up 514.29% from the prior year.
- Capital Expenditures for Q1 2026 stood at $68000.0, up from $32000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $952000.0 in Q4 2022, with the low at -$808000.0 in Q3 2022.
- Average Capital Expenditures over 5 years is $126866.7, with a median of $41000.0 recorded in 2023.
- Year-over-year, Capital Expenditures tumbled 119.85% in 2022 and soared 1984.62% in 2025.
- Tracing SRRK's Capital Expenditures over 5 years: stood at $952000.0 in 2022, then plunged by 95.69% to $41000.0 in 2023, then sank by 46.34% to $22000.0 in 2024, then soared by 45.45% to $32000.0 in 2025, then surged by 112.5% to $68000.0 in 2026.
- The last three Capital Expenditures figures came in at $68000.0 (Q1 2026), $32000.0 (Q4 2025), and $84000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Dec 31, 2022 | 952,000.00 |
| Dec 31, 2022 | 952,000.00 |
| Sep 30, 2022 | -808,000.00 |
| Sep 30, 2022 | -808,000.00 |
| Jun 30, 2022 | 507,000.00 |
| Jun 30, 2022 | 507,000.00 |
| Mar 31, 2022 | 413,000.00 |
| Mar 31, 2022 | 413,000.00 |
| Dec 31, 2021 | 542,000.00 |
| Dec 31, 2021 | 542,000.00 |
| Sep 30, 2021 | 4.07 Mn |
| Sep 30, 2021 | 4.07 Mn |
| Jun 30, 2021 | -1.68 Mn |
| Jun 30, 2021 | -1.68 Mn |
| Mar 31, 2021 | 2.31 Mn |
| Mar 31, 2021 | 2.31 Mn |
| Dec 31, 2020 | 1.97 Mn |
| Dec 31, 2020 | 1.97 Mn |
| Sep 30, 2020 | 1.83 Mn |
| Sep 30, 2020 | 1.83 Mn |
| Jun 30, 2020 | 273,000.00 |
| Jun 30, 2020 | 273,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Mar 31, 2020 | 10,000.00 |
| Dec 31, 2019 | 1.47 Mn |
| Dec 31, 2019 | 1.47 Mn |
| Sep 30, 2019 | 1.62 Mn |
| Sep 30, 2019 | 1.62 Mn |
| Jun 30, 2019 | -456,000.00 |
| Jun 30, 2019 | -456,000.00 |
| Mar 31, 2019 | 483,000.00 |
| Mar 31, 2019 | 483,000.00 |
| Dec 31, 2018 | 701,000.00 |
| Dec 31, 2018 | 701,000.00 |
| Sep 30, 2018 | 599,000.00 |
| Sep 30, 2018 | 599,000.00 |
| Jun 30, 2018 | 179,000.00 |
| Jun 30, 2018 | 179,000.00 |
| Mar 31, 2018 | 13,000.00 |
| Mar 31, 2018 | 13,000.00 |
| Dec 31, 2017 | 302,000.00 |
| Dec 31, 2017 | 302,000.00 |
| Sep 30, 2017 | -150,000.00 |
| Sep 30, 2017 | -150,000.00 |